HomeAI · summaries
Storia in 2 fonti
Zasocitinib outperforms apremilast for high-impact psoriasis sites
Zasocitinib demonstrated high rates of psoriasis clearance for hard-to-treat areas and high-impact sites, Takeda announced in a press release. Approximately 75% of participants with scalp psoriasis and 70% of those with palmoplantar psoriasis who received zasocitinib — a selective oral tyrosine kinase 2 (TYK2) inhibitor that blocks interleukin-23 and other pathways driving psoriasis
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
benzinga.com
Oral Psoriasis Drug From Takeda Demonstrates Strong Skin Clearance in Trials - Takeda Pharmaceutical Co (
Takeda shares positive Phase 3 data for its oral psoriasis drug zasocitinib, showing high skin clearance ahead of its planned FDA filing.
- ·
healio.com
Zasocitinib outperforms apremilast for high-impact psoriasis sites
Zasocitinib demonstrated high rates of psoriasis clearance for hard-to-treat areas and high-impact sites, Takeda announced in a press release. Approximately 75% of participants…